Intrexon | XON - Actif À Court Terme





Actif À Court Terme Changement Date
Agenus USD 133.44M 514K 2025-12
Alaunos Therapeutics USD 2.68M 1.05M 2025-09
Amgen USD 29.06B 1.17B 2025-12
Anika Therapeutics USD 103.36M 1.77M 2025-12
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Incyte USD 5.02B 746.01M 2025-12
Intrexon USD 23.72M 45.04M 2024-06
Karyopharm Therapeutics USD 89.75M 8.12M 2025-09
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Merck USD 47.56B 10.49B 2025-09
Novartis USD 30.46B 2.26B 2025-12
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Thermo Fisher Scientific USD 28.71B 6.41B 2025-12
Veracyte USD 488.38M 39.15M 2025-12
Xencor USD 599.82M 81.38M 2025-12